Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer
Susan Halabi(Duke Medical Center), Eric J. Small(CancerCare Manitoba), Kouros Owzar(Duke University), San‐San Ou, Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Laura Archer(The Royal Wolverhampton NHS Trust)
Cited by 113
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k